scholarly journals Antimicrobial Activities and Cytotoxicity of Sisymbrium irio L Extract against Multi-Drug Resistant Bacteria (MDRB) and Candida albicans

2017 ◽  
Vol 6 (4) ◽  
pp. 1-13 ◽  
Author(s):  
Gamal M. El Sherbiny ◽  
Saad A.M. Moghannem ◽  
Mohammed H. Sharaf
Keyword(s):  
Candida Albicans ◽  
Antimicrobial Activities ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Drug Resistant Bacteria ◽  
Sisymbrium Irio

scholarly journals Potential of Novel Antimicrobial Peptide P3 from Bovine Erythrocytes and Its Analogs To Disrupt Bacterial MembranesIn Vitroand Display Activity against Drug-Resistant Bacteria in a Mouse Model

2015 ◽  
Vol 59 (5) ◽  
pp. 2835-2841 ◽  
Author(s):  
Qinghua Zhang ◽  
Yanzhao Xu ◽  
Qing Wang ◽  
Bolin Hang ◽  
Yawei Sun ◽  
...  
Keyword(s):  
Antimicrobial Activity ◽  
Body Weight ◽  
Mouse Model ◽  
Antimicrobial Activities ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Drug Resistant Bacteria ◽  
Resistant Strains ◽  
Bovine Erythrocytes

ABSTRACTWith the emergence of many antibiotic-resistant strains worldwide, antimicrobial peptides (AMPs) are being evaluated as promising alternatives to conventional antibiotics. P3, a novel hemoglobin peptide derived from bovine erythrocytes, exhibited modest antimicrobial activityin vitro. We evaluated the antimicrobial activities of P3 and an analog, JH-3, bothin vitroandin vivo. The MICs of P3 and JH-3 ranged from 3.125 μg/ml to 50 μg/ml when a wide spectrum of bacteria was tested, including multidrug-resistant strains. P3 killed bacteria within 30 min by disrupting the bacterial cytoplasmic membrane and disturbing the intracellular calcium balance. Circular dichroism (CD) spectrometry showed that P3 assumed an α-helical conformation in bacterial lipid membranes, which was indispensable for antimicrobial activity. Importantly, the 50% lethal dose (LD50) of JH-3 was 180 mg/kg of mouse body weight after intraperitoneal (i.p.) injection, and no death was observed at any dose up to 240 mg/kg body weight following subcutaneous (s.c.) injection. Furthermore, JH-3 significantly decreased the bacterial count and rescued infected mice in a model of mouse bacteremia. In conclusion, P3 and an analog exhibited potent antimicrobial activities and relatively low toxicities in a mouse model, indicating that they may be useful for treating infections caused by drug-resistant bacteria.

scholarly journals Extremophilic actinomycetes isolated from soil in Kazakhstan: Classification and antimicrobial activities

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Ainur Zhulamanova ◽  
Zhanat Koshenov ◽  
Saikal Shamkeeva ◽  
Zhannur Markhametova ◽  
Diyora Abdukhakimova ◽  
...  
Keyword(s):  
Extreme Environment ◽  
Antimicrobial Activities ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Antimicrobial Compounds ◽  
Antimicrobial Compound ◽  
Future Studies ◽  
Drug Resistant Bacteria ◽  
Modified Media ◽  
Novel Agent

Extremophilic actinomycetes species are capable of surviving in extreme environment and producing antibiotics. In this study, we hypothesize that extremophiles produce antimicrobial compounds that are potentially novel agent(s) effective against drug resistant pathogens. The goal of this study is to test inhibitory activity of the extracts derived from extremophilic actinomycetes species against the most prevalent drug-resistant bacteria in Kazakhstani hospitals, and preliminarily analyze chemical composition of the active extracts. Actinomycetes species isolated from the soil of Kazakhstan were cultured in modified media mimicking extreme environment the species were isolated from. Antimicrobial compound(s) extracted with organic solvent were tested against conditionally pathogenic and multi-drug resistant pathogens Acinetobacter baumanni and Pseudomonas aeruginosa. Our study generated promising results regarding the potential discovery of novel components effective against drug resistant pathogens. Future studies will focus on further chemical analysis to identify the active component within these extremophilic extracts.

Novel Antibiotics from Marine Sources

2011 ◽  
Vol 4 (3) ◽  
pp. 1446-1461 ◽  
Author(s):  
E.A. Martis ◽  
G M Doshi ◽  
G V Aggarwal ◽  
P P Shanbhag
Keyword(s):  
Pharmaceutical Industry ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Drug Resistant Bacteria ◽  
Terrestrial Life ◽  
New Antibiotics ◽  
Antibiotic Compounds ◽  
New Generation ◽  
Novel Antibiotics ◽  
Untapped Resource

With the emergence of newer diseases, resistant forms of infectious diseases and multi-drug resistant bacteria, it has become essential to develop novel and more effective antibiotics. Current antibiotics are obtained from terrestrial life or made synthetically from intermediates. The ocean represents virtually untapped resource from which novel antibiotic compounds can be discovered. It is the marine world that will provide the pharmaceutical industry with the next generation of antibiotics. Marine antibiotics are antibiotics obtained from marine organisms. Scientists have reported the discovery of various antibiotics from marine bacteria (aplasmomycin, himalomycins, and pelagiomycins), sponges (Ara C, variabillin, strobilin, ircinin-1, aeroplysin, 3,5-dibromo-4-hydroxyphenylacetamide), coelenterates (asperidol and eunicin), mollusks (laurinterol and pachydictyol), tunicates (geranylhydroquinone and cystadytins), algae (cycloeudesmol, aeroplysinin-1(+), prepacifenol and tetrabromoheptanone), worms (tholepin and 3,5-dibromo-4-hydroxybezaldehyde), and actinomycetes (marinomycins C and D). This indicates that the marine environment, representing approximately half of the global diversity, is an enormous resource for new antibiotics and this source needs to be explored for the discovery of new generation antibiotics. The present article provides an overview of various antibiotics obtained from marine sources.

Re-challenging antibiotic resistance with Daniel Berman

2020 ◽  
Author(s):  
Daniel Berman
Keyword(s):  
Bacterial Infections ◽  
Point Of Care ◽  
Healthcare Setting ◽  
Rapid Diagnostic Tests ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Drug Resistant Bacteria ◽  
Global Threat ◽  
The Right ◽  
Point Of Care Tests

How can we prevent the rise of resistance to antibiotics? In this video, Daniel Berman,  Nesta Challenges, discusses the global threat of AMR and how prizes like the Longitude Prize can foster the development of rapid diagnostic tests for bacterial infections, helping to contribute towards reducing the global threat of drug resistant bacteria. Daniel outlines how accelerating the development of rapid point-of-care tests will ensure that bacterial infections are treated with the most appropriate antibiotic, at the right time and in the right healthcare setting.

Sign in / Sign up

Export Citation Format

Share Document